Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Furudate, Sadanori, Hidaka, Takanori, Aiba, Setsuya
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884646/
https://ncbi.nlm.nih.gov/pubmed/29643991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24509
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares